Skip to main content
OpenTrials
Completed

NCT Number: NCT04169581

A Deep Learning Framework for Pediatric TLE Detection Using 18F-FDG-PET Imaging

This study aims to use radiomics analysis and deep learning approaches for seizure focus detection in pediatric patients with temporal lobe epilepsy (TLE). Ten positron emission tomograph (PET) radiomics features related to pediatric temporal bole epilepsy are extracted and modelled, and the Siamese network is trained to automatically locate epileptogenic zones for assistance of diagnosis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 year–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Nuclear Medicine and PET/CT Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, 310009, China

About this study

Purpose:The key to successful epilepsy control involves locating epileptogenic focus before treatment. 18F-FDG PET has been considered as a powerful neuroimaging technology used by physicians to assess patients for epilepsy. However, imaging quality, viewing angles, and experiences may easily degrade the consistency in epilepsy diagnosis. In this work, the investigators develop a framework that combines radiomics analysis and deep learning techniques to a computer-assisted diagnosis (CAD) method to detect epileptic foci of pediatric patients with temporal lobe epilepsy (TLE) using PET images.

Methods:Ten PET radiomics features related to pediatric temporal bole epilepsy are first extracted and modelled. Then a neural network called Siamese network is trained to quanti-fy the asymmetricity and automatically locate epileptic focus for diagnosis.The performance of the proposed framework was tested and compared with both the state-of-art clinician software tool and human physicians with different levels of experiences to validate the accuracy and consistency.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical diagnosis of temporal lobe epilepsy.
  • Age range from six to eighteen years old.
  • Underwent PET, EEG, computed tomography (CT) and MRI.

Exclusion criteria

  • Image quality is unsatisfactory (e.g. severe image artifacts due to head movement).
  • 18F-FDG PEG examination is negative.
  • Clinical data is incomplete.
  • EEG or MRI report is missing.

Treatment and study plan

Primary outcomes

  1. The 'area under curve' (AUC ) of our model in detection performance

    Time frame: Through study completion, about 1 year

    To evaluate the performance of our model, the investigators calculated the AUC of our model for normal or abnormal classification campared with different methods and and physicians with different levels.

Secondary outcomes

  1. The 'dice similarity coefficient' (DSC) of our model in detection performance

    Time frame: Through study completion, about 3 months

    The accuracy of focus lesion detection is quantitatively measured through the metric of 'dice similarity coefficient' (DSC) by comparing the spatial overlap between the marked regions between the reference standard and the subject method under test.

Sponsors and collaborators

Lead sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Other

Registry information

Official study title

Symmetricity-Driven Learning Framework for Pediatric Temporal Lobe Epilepsy Detection Using 18F-FDG-PET Imaging

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Nov 20, 2019
Registry last updated
Jan 2, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.